Clinical Trials

Open Trials


At Shenandoah Oncology, research is an integral part of our comprehensive efforts to provide cancer patients in our community with access to the latest and most advanced therapies and treatment options.  As a member of US Oncology Network and as a clinical research affiliate of VCU Massey Cancer Center, we are pleased to share this list of clinical trials currently enrolling at our practice.

BREAST CANCER - ADJUVANT

USOR 22-326: Phase 3, open-label, randomized study to assess the efficacy and safety of camizestrant (AZD9833, a next-generation, oral selective estrogen receptor degrader) vs standard endocrine therapy (aromatase inhibitor or tamoxifen) as adjuvant treatment for patients with ER+/HER2- early breast cancer and an intermediate-high or high risk of recurrence who have completed definitive locoreginal treatment and have no evidence of disease (CAMBRIA-2). Click here to learn more

LUNG

USOR 22-285: Molecularly informed lung cancer treatment in a community cancer network: A longitudinal prospective real-world evidence study (MYLUNG Consortium Part 3 Observations Study). Click here to learn more

PREVENTION

URCC 19-185: Multicenter, randomized trial comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) vs. Healthy Eating Education Learning (HEAL) for treatment of insomnia. Click here to learn more

SOLID TUMOR

USOR 21-236: Detecting cancers earlier through elective plasma-based CancerSEEK testing. Patients age 50 years old or greater with untreated solid tumors will undergo a one-time blood draw to obtain clinically characterized, whole blood specimens from cancer subjects to develop and refine assays for cancer in the blood.

USOR 22-311: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Click here to learn more

UROTHELIAL– METASTATIC

A032001: Phase 3, randomized trial of maintenance cabozantinib & avelumab vs maintenance avelumab alone after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer.  Click here to learn more

Learn More